ClinicalTrials.gg
CompletedNCT05478499Updated Oct 28, 2025Results posted

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

A Phase 4 interventional study of Deucravacitinib and Placebo in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 29 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
11th of 26
154 · median 102
Started
2022
with 1 other
Phase 4
8 of 26
2 open now
Registered
14th of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 4, and was the 14th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Scalp Psoriasis
  • BMS-986165
  • Deucravacitinib
  • Psoriasis
  • Psoriasis Special Sites
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator
  2. Deemed by the Investigator to be a candidate for phototherapy or systemic therapy
  3. Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1
  4. ≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1
  5. Evidence of plaque psoriasis in a non-scalp area
  6. Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis

Exclusion criteria

Exclusion Criteria:

  • Target Disease Exceptions:

    1. Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Deucravacitinib

    Drug: Deucravacitinib

  • Placebo comparator
    Placebo then Deucravacitinib

    Drug: Deucravacitinib · Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986165

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16

    ss-PGA 0/1 response as a percentage of participants with an ss-PGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16. Scalp lesions are evaluated in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Percentage of Participants With a Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16

    PSSI 90 response as a percentage of participants who achieve at least 90% improvement from baseline in the PSSI score at Week 16. PSSI assesses severity of scalp disease in participants with scalp involvement with a 5-point Likert-type scale on the clinical parameters of erythema, induration, and desquamation. The scores are summed and multiplied by an integer (0 to 6) that represents the area of affected scalp. The PSSI score ranges from 0 to 72 with higher scores indicating more severe symptoms.

    Time frame: Baseline and Week 16

  2. Change From Baseline in Scalp-specific Itch Numerical Rating Scale (NRS) Score at Week 16

    Change from baseline in scalp-specific itch numerical rating scale (NRS) score at week 16. The scalp-specific itch NRS is an 11-point horizontal scale anchored at 0 and 10 with 0 representing "no scalp itch" and 10 representing "worst scalp itch imaginable.". Overall severity of a participant's itching from scalp psoriasis is indicated by selecting the number that best describes the worst level of scalp itching within the past 24 hours.

    Time frame: Baseline and Week 16

  3. Percentage of Participants With a Static Physician Global Assessment Score of 0 or 1 (s-PGA 0/1) at Week 16

    s-PGA 0/1 response as a percentage of participants with an s-PGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16. The s-PGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The s-PGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

    Time frame: Baseline and Week 16

  4. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relation with this treatment.

    Time frame: From week 0 through week 16

  5. Number of Participants Experiencing Serious Treatment Emergent Adverse Events (TEAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From week 0 through week 16

  6. Number of Participants Experiencing Laboratory Test Results of Worst Toxicity Grade

    Laboratory test results summary of Worst toxicity grade in SI units for hematology and chemistry using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1= mild and asymptomatic; Grade 2= moderate requiring minimal, local or noninvasive intervention; Grade 3= severe or medically significant but not immediately life-threatening; Grade 4= events are usually severe enough to require hospitalization.

    Time frame: Week 0 through Week 16

  7. Number of Participants Experiencing Laboratory Abnormalities in Potential Drug-Induced Liver Injury Tests

    Number of participants with laboratory abnormalities in potential drug-induced liver injury tests. ALT=alanine aminotransferase AST=aspartate aminotransferase ULN=upper limit of normal

    Time frame: Week 0 through Week 16

  8. Number of Participants With Abnormalities in Vital Signs

    Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure.

    Time frame: Week 0 through Week 16

07

Results

Posted Mar 13, 2025

Participant flow

Placebo Controlled: Week 0 - 16
Participant flow — Placebo Controlled: Week 0 - 16
MilestoneDeucravacitinibPlacebo
Started10351
Completed9445
Not completed96
Withdrew: Adverse event42
Withdrew: Withdrawal by subject32
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up10
Withdrew: Other reasons02
Active Treatment: Week 16 - Week 52
Participant flow — Active Treatment: Week 16 - Week 52
MilestoneDeucravacitinibPlacebo
Started9445
Completed8039
Not completed146
Withdrew: Withdrawal by subject42
Withdrew: Lack of efficacy41
Withdrew: Adverse event40
Withdrew: Lost to follow-up12
Withdrew: Death10
Withdrew: Non-compliance with protocol01

Outcome measures

PrimaryPercentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16

ss-PGA 0/1 response as a percentage of participants with an ss-PGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16. Scalp lesions are evaluated in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease.

Time frame:
Baseline and Week 16
Reported as:
Number · Percentage of responders
Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16
Percentage of respondersDeucravacitinibPlacebo
Full Analysis Set48.5 (38.6 to 58.6)13.7 (5.7 to 26.3)
Patient sub-population (s-PGA ≥ 3)50.0 (39.6 to 60.4)12.8 (4.8 to 25.7)
Statistical analysis
  • Deucravacitinib vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 6.2 · 95% CI 2.5 to 15.3Cochran-Mantel-Haenszel
  • Deucravacitinib vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 7.0 · 95% CI 2.7 to 18.4Cochran-Mantel-Haenszel
SecondaryPercentage of Participants With a Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16

PSSI 90 response as a percentage of participants who achieve at least 90% improvement from baseline in the PSSI score at Week 16. PSSI assesses severity of scalp disease in participants with scalp involvement with a 5-point Likert-type scale on the clinical parameters of erythema, induration, and desquamation. The scores are summed and multiplied by an integer (0 to 6) that represents the area of affected scalp. The PSSI score ranges from 0 to 72 with higher scores indicating more severe symptoms.

Time frame:
Baseline and Week 16
Reported as:
Number · Percentage of responders
Percentage of Participants With a Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16
Percentage of respondersDeucravacitinibPlacebo
Full Analysis Set38.8 (29.4 to 48.9)2.0 (NA to 10.4)
Patient sub-population (s-PGA ≥ 3)40.6 (30.7 to 51.1)2.1 (NA to 11.3)
Statistical analysis
  • Deucravacitinib vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 40.2 · 95% CI 4.6 to 352.0Cochran-Mantel-Haenszel
  • Deucravacitinib vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 37.3 · 95% CI 4.4 to 317.6Cochran-Mantel-Haenszel
SecondaryChange From Baseline in Scalp-specific Itch Numerical Rating Scale (NRS) Score at Week 16

Change from baseline in scalp-specific itch numerical rating scale (NRS) score at week 16. The scalp-specific itch NRS is an 11-point horizontal scale anchored at 0 and 10 with 0 representing "no scalp itch" and 10 representing "worst scalp itch imaginable.". Overall severity of a participant's itching from scalp psoriasis is indicated by selecting the number that best describes the worst level of scalp itching within the past 24 hours.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a scale
Change From Baseline in Scalp-specific Itch Numerical Rating Scale (NRS) Score at Week 16
Score on a scaleDeucravacitinibPlacebo
Full Analysis Set-3.2 ± 2.95-0.7 ± 2.27
Patient sub-population (s-PGA ≥ 3)-3.3 ± 2.87-0.9 ± 2.29
Statistical analysis
  • Deucravacitinib vs Placebo · analysis of covariance model · p = <0.0001 · Adjusted mean difference: -2.5 · 95% CI -3.3 to -1.6analysis of covariance model
  • Deucravacitinib vs Placebo · analysis of covariance model · p = <0.0001 · Adjusted mean difference: -2.4 · 95% CI -3.3 to -1.5analysis of covariance model
SecondaryPercentage of Participants With a Static Physician Global Assessment Score of 0 or 1 (s-PGA 0/1) at Week 16

s-PGA 0/1 response as a percentage of participants with an s-PGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16. The s-PGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The s-PGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Time frame:
Baseline and Week 16
Reported as:
Number · Percentage of responders
Percentage of Participants With a Static Physician Global Assessment Score of 0 or 1 (s-PGA 0/1) at Week 16
Percentage of respondersDeucravacitinibPlacebo
Percentage of Participants With a Static Physician Global Assessment Score of 0 or 1 (s-PGA 0/1) at Week 1651.0 (40.6 to 61.4)4.3 (0.5 to 14.5)
Statistical analysis
  • Deucravacitinib vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 23.9 · 95% CI 5.4 to 105.6Cochran-Mantel-Haenszel
SecondaryNumber of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relation with this treatment.

Time frame:
From week 0 through week 16
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
ParticipantsDeucravacitinibPlacebo
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)7326
SecondaryNumber of Participants Experiencing Serious Treatment Emergent Adverse Events (TEAEs)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From week 0 through week 16
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Treatment Emergent Adverse Events (TEAEs)
ParticipantsDeucravacitinibPlacebo
Number of Participants Experiencing Serious Treatment Emergent Adverse Events (TEAEs)11
SecondaryNumber of Participants Experiencing Laboratory Test Results of Worst Toxicity Grade

Laboratory test results summary of Worst toxicity grade in SI units for hematology and chemistry using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1= mild and asymptomatic; Grade 2= moderate requiring minimal, local or noninvasive intervention; Grade 3= severe or medically significant but not immediately life-threatening; Grade 4= events are usually severe enough to require hospitalization.

Time frame:
Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants Experiencing Laboratory Test Results of Worst Toxicity Grade
ParticipantsDeucravacitinibPlacebo
Basophils (10^9/L) Grade 1-400
Eosinophils (10^9/L) Grade 142
Eosinophils (10^9/L) Grade 2-400
Hemoglobin (g/L) Grade 154
Hemoglobin (g/L) Grade 210
Hemoglobin (g/L) Grade 300
Leukocytes (10^9/L) Grade 181
Leukocytes (10^9/L) Grade 201
Leukocytes (10^9/L) Grade 3-400
Lymphocytes Blood Test (10^9/L) Grade 111
Lymphocytes Blood Test (10^9/L) Grade 210
Lymphocytes Blood Test (10^9/L) Grade 3-400
Lymphocytes Plasma Test (10^9/L) Grade 111
Lymphocytes Plasma Test (10^9/L) Grade 210
Lymphocytes Plasma Test (10^9/L) Grade 3-400
Neutrophils (x10^9/L) Grade 152
Neutrophils (x10^9/L) Grade 2-400
Platelets (10^9/L) Grade 1-400
Alanine Aminotransferase (U/L) Grade 188
Alanine Aminotransferase (U/L) Grade 201
Alanine Aminotransferase (U/L) Grade 3-400
Albumin (g/L) Grade 1-400
Alkaline Phosphatase (U/L) Grade 112
Alkaline Phosphatase (U/L) Grade 2-400
Aspartate Aminotransferase (U/L) Grade 155
Aspartate Aminotransferase (U/L) Grade 2-400
Bilirubin (umol/L) Grade 153
Bilirubin (umol/L) Grade 210
Bilirubin (umol/L) Grade 3-400
Calcium (mmol/L) Grade 110
Calcium (mmol/L) Grade 2-400
Chloride (mmol/L) Grade 1-400
Cholesterol (mmol/L) Grade 150
Cholesterol (mmol/L) Grade 2-400
Creatine Kinase (U/L) Grade 1-40—
Creatinine (umol/L) Grade 130
Creatinine (umol/L) Grade 210
Creatinine (umol/L) Grade 3-400
Direct Bilirubin (umol/L) Grade 1-400
Glucose (mmol/L) Grade 120
Glucose (mmol/L) Grade 2-400
Lactate Dehydrogenase (U/L) Grade 1-40—
Magnesium (mmol/L) Grade 1-40—
Phosphate (mmol/L) Grade 1-400
Potassium (mmol/L) Grade 162
Potassium (mmol/L) Grade 281
Potassium (mmol/L) Grade 301
Potassium (mmol/L) Grade 400
Sodium (mmol/L) Grade 102
Sodium (mmol/L) Grade 210
Sodium (mmol/L) Grade 3-400
Triglycerides (mmol/L) Grade 1277
Triglycerides (mmol/L) Grade 223
Triglycerides (mmol/L) Grade 310
Triglycerides (mmol/L) Grade 401
Urate (umol/L) Grade 1-40—
Urea Nitrogen (mmol/L) Grade 1-400
SecondaryNumber of Participants Experiencing Laboratory Abnormalities in Potential Drug-Induced Liver Injury Tests

Number of participants with laboratory abnormalities in potential drug-induced liver injury tests. ALT=alanine aminotransferase AST=aspartate aminotransferase ULN=upper limit of normal

Time frame:
Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants Experiencing Laboratory Abnormalities in Potential Drug-Induced Liver Injury Tests
ParticipantsDeucravacitinibPlacebo
ALT or AST > 3 X ULN01
ALT or AST > 5 X ULN00
Total Bilirubin > 2 X ULN00
ALT or AST > 3 X ULN and total bilirubin > 2 X ULN on the same day00
SecondaryNumber of Participants With Abnormalities in Vital Signs

Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure.

Time frame:
Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Vital Signs
ParticipantsDeucravacitinibPlacebo
HEART RATE (BEATS/MIN): VALUE > 100 AND CHANGE FROM BASELINE > 3000
HEART RATE (BEATS/MIN): VALUE < 55 AND CHANGE FROM BASELINE < -1513
HEART RATE (BEATS/MIN): NOT REPORTED00
SYSTOLIC BLOOD PRESSURE (MMHG): VALUE > 140 AND CHANGE FROM BASELINE > 2034
SYSTOLIC BLOOD PRESSURE (MMHG): VALUE < 90 AND CHANGE FROM BASELINE < -2000
SYSTOLIC BLOOD PRESSURE (MMHG): NOT REPORTED00
DIASTOLIC BLOOD PRESSURE (MMHG): VALUE > 90 AND CHANGE FROM BASELINE > 1083
DIASTOLIC BLOOD PRESSURE (MMHG): VALUE < 55 AND CHANGE FROM BASELINE < -1002
DIASTOLIC BLOOD PRESSURE (MMHG): NOT REPORTED00

Adverse events

Collected over Participants were assessed for all-cause mortality from their first dose to their primary data cut-off (Up to 24 months). SAEs and Other AEs were assessed from first dose up to 30 days post last dose (Up to 13 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Controlled - Deucravacitinib0/103 (0%)1/103 (1%)47/103 (45.6%)
Placebo Controlled - Placebo0/51 (0%)1/51 (2%)14/51 (27.5%)
Active Treatment - Deucravacitinib - Deucravacitinib1/94 (1.1%)4/94 (4.3%)42/94 (44.7%)
Active Treatment - Placebo - Deucravacitinib0/45 (0%)0/45 (0%)16/45 (35.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo Controlled - DeucravacitinibPlacebo Controlled - PlaceboActive Treatment - Deucravacitinib - DeucravacitinibActive Treatment - Placebo - Deucravacitinib
Atrial fibrillationCardiac disorders0/1031/510/940/45
Myocardial infarctionCardiac disorders0/1030/511/940/45
Ligament disorderMusculoskeletal and connective tissue disorders0/1030/511/940/45
Colorectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1030/511/940/45
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1030/511/940/45
Meniscus injuryInjury, poisoning and procedural complications1/1030/510/940/45
Most frequent other events
Most frequent other events
EventPlacebo Controlled - DeucravacitinibPlacebo Controlled - PlaceboActive Treatment - Deucravacitinib - DeucravacitinibActive Treatment - Placebo - Deucravacitinib
NasopharyngitisInfections and infestations16/1037/5122/948/45
COVID-19Infections and infestations6/1034/5112/944/45
Upper respiratory tract infectionInfections and infestations12/1032/5111/943/45
AcneSkin and subcutaneous tissue disorders10/1030/511/941/45
HeadacheNervous system disorders8/1032/512/941/45
PsoriasisSkin and subcutaneous tissue disorders2/1033/514/940/45
Acne pustularInfections and infestations6/1030/513/940/45

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DeucravacitinibPlaceboTotal
Mean42.8 ± 15.7043.2 ± 13.0842.9 ± 14.84
Sex: Female, Male
Sex: Female, Male(Participants)DeucravacitinibPlaceboTotal
Female452065
Male583189
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DeucravacitinibPlaceboTotal
Hispanic or Latino6814
Not Hispanic or Latino9543138
Unknown or Not Reported202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DeucravacitinibPlaceboTotal
American Indian or Alaska Native000
Asian325
Black or African American527
Native Hawaiian or other pacific islander000
White9347140
Other202
08

Study locations

29 sites
  • Local Institution - 0001
    Hot Springs, Arkansas 71913, United States
  • Local Institution - 0007
    Indianapolis, Indiana 46256, United States
  • Local Institution - 0041
    Louisville, Kentucky 40217, United States
  • Local Institution - 0022
    Rockville, Maryland 20850, United States
  • Local Institution - 0008
    Beverly, Massachusetts 01915, United States
  • Local Institution - 0047
    Bloomfield Hills, Michigan 48302, United States
  • Local Institution - 0002
    New Brighton, Minnesota 55432, United States
  • Local Institution - 0049
    East Windsor, New Jersey 08520, United States
  • Local Institution - 0051
    Kew Gardens, New York 11415, United States
  • Local Institution - 0003
    Portland, Oregon 97201, United States
  • Local Institution - 0005
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0033
    Houston, Texas 77004, United States
  • Local Institution - 0004
    San Antonio, Texas 78229, United States
  • Local Institution - 0006
    Norfolk, Virginia 23502, United States
  • Local Institution - 0019
    Paris, 75010, France
  • Local Institution - 0040
    Romans-sur-Isère, 26102, France
  • Local Institution - 0044
    Rouen, 76031, France
  • Local Institution - 0038
    Witten, Deutschland 58454, Germany
  • Local Institution - 0013
    Frankfurt am Main, Hesse 60590, Germany
  • Local Institution - 0048
    Hamburg, 20246, Germany
  • Local Institution - 0012
    Lübeck, 23538, Germany
  • Local Institution - 0011
    Mahlow, 15831, Germany
  • Local Institution - 0026
    Krakow, 30438, Poland
  • Local Institution - 0017
    Lodz, 90-436, Poland
  • Local Institution - 0014
    Rzeszów, 35-055, Poland
  • Local Institution - 0015
    Wroclaw, 51-685, Poland
  • Local Institution - 0031
    London, Greater London SE1 9RT, United Kingdom
  • Local Institution - 0045
    Salford, Greater Manchester M6 8HD, United Kingdom
  • Local Institution - 0039
    Southampton, HAMPSHIRE SO16 6DU, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jan 2024, 15 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 15 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2022
First posted
Jul 28, 2022
StartActual
Oct 6, 2022
Primary completionActual
Jan 11, 2024
CompletionActual
Oct 17, 2024
Results first posted
Mar 13, 2025
Last update
Oct 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05478499
Responsible party
Sponsor
First posted
Jul 28, 2022
Start date
Oct 6, 2022
Primary completion
Jan 11, 2024
Completion
Oct 17, 2024
Results posted
Mar 13, 2025
Last update
Oct 28, 2025

Study contacts

Bristol-Myers Squibb
study chair · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion